Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have received a consensus rating of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $66.75.

A number of research analysts have issued reports on ARCT shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright reiterated a "buy" rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Monday, January 13th.

Arcturus Therapeutics Trading Down 1.3 %

NASDAQ ARCT traded down $0.22 during trading hours on Friday, reaching $16.79. The company's stock had a trading volume of 225,175 shares, compared to its average volume of 370,806. The stock has a market cap of $454.84 million, a PE ratio of -7.56 and a beta of 2.63. The business has a 50-day simple moving average of $17.46 and a 200 day simple moving average of $19.85. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. During the same period in the prior year, the business earned ($0.61) EPS. As a group, equities analysts predict that Arcturus Therapeutics will post -2.31 EPS for the current year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new position in Arcturus Therapeutics in the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd. grew its position in Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after acquiring an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Arcturus Therapeutics during the 2nd quarter valued at $142,000. Point72 DIFC Ltd bought a new stake in Arcturus Therapeutics in the second quarter worth $188,000. Finally, SG Americas Securities LLC bought a new stake in Arcturus Therapeutics in the third quarter worth $191,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.